Background: Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the pathogenesis of acute coronary syndrome. We have recently demonstrated that the administration of edaravone before reperfusion attenuated reperfusion injury in patients with acute myocardial infarction (AMI). Methods: Plasma MCP-1 levels were measured in 45 consecutive patients with AMI (edaravone group, n = 25; control group, n = 20). In the edaravone group, 30 mg edaravone was intravenously infused just before reperfusion. Plasma samples were obtained before and at 24 h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular events were defined as cardiac death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion. Results: Plasma MCP-1 levels were not different between the two groups before reperfusion. Compared with the placebo group, the edaravone group had statistically lower maximum creatine kinase-MB levels (218 ± 31 IU/l versus 145 ± 21 IU/l, p < 0.05) and plasma MCP-1 levels on day 3 after reperfusion (873 ± 118 pg/ml versus 516 ± 66 pg/ml, p < 0.05). Heart failure requiring rehospitalization occurred in four * Corresponding author.
Introduction
Myocardial reperfusion is necessary for the salvage and recovery of ischemic myocardium. Early reperfusion has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injury [1] [2] [3] .
Myocardial ischemia and reperfusion injury are believed to be associated with inflammatory reactions involving various types of cells and cytokines [4] . Local and systemic inflammatory reactions play a key role in the extension of myocardial tissue injury and adverse effects during left ventricular (LV) recovery [5] . Some experimental studies have demonstrated the importance of monocyte/macrophage infiltration after myocardial infarction (MI) [6, 7] .
Monocyte chemoattractant protein-1 (MCP-1) belongs to the CC chemokine subfamily with two adjacent cysteine residues and serves as a chemotactic and activating factor for the recruitment of monocytes [8] . MCP-1 is secreted by various types of cells, such as monocytes/macrophages, T lymphocytes, endothelial cells, vascular smooth muscle cells, and myocytes [8] [9] [10] . Many experimental and clinical studies have demonstrated up-regulation of MCP-1 after MI, with recruitment of monocytes/macrophages to the ischemic myocardium [11] [12] [13] .
The ability to control the activity of macrophages or other cells by modulating the production or inhibiting the action of MCP-1 may lead to the design of new therapies to prevent reperfusion injury. In an animal study, CC chemokine receptor-2 (CCR-2) deficiency attenuated oxidative stress and reduced infarct size after myocardial ischemia-reperfusion [14] . Recently, large population studies demonstrated that MCP-1 may have value as a biomarker for risk stratification in both the initial and the chronic phases of acute coronary syndromes, and support additional investigation of MCP-1 (and CCR-2) as therapeutic targets [15] .
Edaravone
(3-methyl-1-phenyl-2-pyrazolin-5one) has a low molecular weight (174.20 kDa), is lipophilic, and is readily accessible to tissue [16, 17] . Edaravone has the ability to scavenge toxic free radicals; moreover, it has been shown to inhibit vascular endothelial cell injury and to inhibit brain edema caused by free radical-induced lipid peroxidation [18] . We have already reported that the administration of edaravone just prior to myocardial reperfusion attenuated both enzymatic infarct size and reperfusion arrhythmias in patients with AMI [19, 20] .
In the present study, we examined the efficacy of edaravone on plasma MCP-1 levels in patients with AMI.
Methods

Patients and study design
The present study was a randomized, placebocontrolled, open-label study involving 50 patients with AMI admitted to our institution from November 2002 to April 2006. The patients fulfilled the following inclusion criteria: (1) admission within 6 h of symptom onset; (2) coronary angiography performed immediately after admission; and (3) emergency percutaneous coronary intervention (PCI). The diagnosis of AMI was made on the basis of chest pain persisting for ≥30 min, ST-segment elevation of >0.2 mV in ≥2 continuous leads on a standard 12-lead electrocardiogram (ECG), and elevation of serum creatine kinase (CK)-MB isoenzyme levels to more than twice the upper limit of normal. During the study period, 50 patients were enrolled that had an occluded culprit lesion in the proximal segment of a major coronary artery that persisted after an intra-coronary nitrate injection. At first, 50 patients were randomly divided into an edaravone group (n = 25) or a control group (n = 25). Exclusion criteria included current use of edaravone, age <18 years, an inability to provide informed consent, recent major surgery or trauma, acute infection, antimicrobial treatment, corticosteroid treatment, chronic obstructive lung disease, malignancy, renal insufficiency (defined as serum creatinine >1.2 mg/dl), and altered hepatic function (defined as serum aspartate aminotransferase >50 IU/l, alanine aminotransferase >50 IU/l, and total bilirubin >1.2 mg/dl). Among the 50 patients, five patients in the control group were excluded from the dataset for the following reasons: loss of blood sampling (three patients) and apparently artifactual MCP-1 levels (two patients). Finally, 45 of 50 patients (edaravone group n = 25, control group n = 20) were studied.
In the edaravone group, 30 mg edaravone was intravenously infused for 10 min as soon as occlusion of the infarct-related coronary artery was confirmed by coronary angiography; the control group received the same volume of saline solution. The study protocol was in agreement with the guidelines of the Ethics Committee at our institution, and written informed consent was obtained from each patient before enrollment.
Reperfusion therapy
Primary PCI was performed instantly, and thus, coronary reperfusion was obtained immediately after completion of the edaravone or saline infusion. Pre-hospital thrombolysis, distal protection devices, and intra-coronary thrombolysis, which have been shown to improve AMI prognosis were not performed in the present study. In all patients, coronary stents were successfully implanted at the culprit lesion to prevent acute coronary occlusion, which is likely to occur after balloon angioplasty alone. The use of concomitant medications was similar between the two groups. Patients were routinely treated with aspirin (100-200 mg/day, indefinitely) and ticlopidine (200 mg/day for 2 weeks after coronary stenting). In both groups, an initial bolus of 130 U/kg heparin was given; additional boluses of heparin were administered during the procedure to maintain an activated clotting time of 300 s.
Determination of infarct size and monitoring of reperfusion arrhythmias
Blood samples were obtained before and immediately after reperfusion, and then at 6, 12, 18, 24 h and 3, 5, 7, and 14 days after reperfusion. Serum biomarkers were measured by using a standard enzymatic method. We monitored the ECGs continuously and compared the incidence of reperfusion arrhythmias such as ventricular tachycardia or ventricular fibrillation between the two groups. Two-dimensional echocardiography for analysis of LV ejection fraction (LVEF) was performed by cardiologists immediately after reperfusion therapy (acute phase), 2 weeks after admission (chronic phase), and 12 months after reperfusion therapy. LVEF was calculated by the modified Simpson's rule algorithm.
Cardiovascular events
We defined cardiovascular events during admission as any of the following: (1) cardiac death;
(2) subacute thrombosis; or (3) ventricular tachycardia. Cardiac death was defined as death from MI. Subacute stent thrombosis was defined as MI or angiographic occlusion of a stent, with thrombolysis in myocardial infarction (TIMI) flow 0-1 after the first 24 h and during the first month. Ventricular tachycardia was defined as ≥6 consecutive premature ventricular contractions. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion therapy.
Serial determination of plasma MCP-1 levels
Plasma levels of MCP-1 antigen were measured using a commercially available enzyme-linked immunosorbent assay kit (MCP-1: HyCult Biotechnology bv, Uden, the Netherlands). The intra-assay and inter-assay coefficients of variation at an MCP-1 antigen level of 630 pg/ml were 10.3% and 4.9%, respectively.
Statistical analysis
All data are expressed as the mean ± SEM. Comparisons of age, body mass index, levels of hemoglobin, serum cholesterol, triglyceride, hemoglobin A 1 c, C-reactive protein, CK, CK-MB, brain natriuretic peptide (BNP), duration from onset to reperfusion and reperfusion to maximum (Max) CK-MB between the two groups were performed with a one-way analysis of variance (ANOVA) followed by Scheffé's test and the other baseline characteristics were compared by using the chi-square test. LVEF was compared by two-way ANOVA for repeated measures. When the results were significant, the significance level for correlations is given after applying the Bonferroni method. p-Values <0.05 were considered to be statistically significant.
Results
Comparison of clinical characteristics
The baseline clinical characteristics of the study subjects are shown in Table 1 . There were no significant differences in age, male gender, coronary risk factors, prior MI, history of congestive heart failure (CHF), atrial fibrillation, multivessel disease, hemoglobin, lipid profiles, and the rate of anterior MI between the two groups. There were also no differences in duration from onset to reperfusion and reperfusion to Max CK-MB between the two groups. The rate of Forrester classification II-IV was statistically higher in the edaravone group than in the control group (p < 0.05). There were no significant differences in the use of pharmacotherapy, including statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), ␤-blockers, calcium-channel blockers, or nitrates between the two groups.
Comparison of enzymatic infarct size and cardiac events during admission
In all patients, primary PCI was performed on the culprit lesion and successful reperfusion (defined as the achievement of TIMI grade 3 flow) was obtained within 6 h of symptom onset. Max CK-MB levels were significantly lower in the edaravone group than in the control group (145 ± 21 IU/l versus 218 ± 31 IU/l, p < 0.05) as shown in Table 2 . All patients had systolic or diastolic dysfunction. Five of twenty patients had LVEF < 50% in the control group, and 7 of 25 patients in the edaravone group. There were no significant differences in the rate of LVEF < 50% between the two groups (p > 0.99). Some improvement in LVEF was observed during the acute phase in the edaravone group (57 ± 2% versus 51 ± 3%, p < 0.05). At 2 weeks after reper-fusion therapy, LVEF was ameliorated in the two groups, but differences in LVEF disappeared during the chronic phase (59 ± 2% versus 55 ± 2%, NS). At 12 months after reperfusion therapy, LVEF was statistically higher in the edaravone group than in the control group (62 ± 2% versus 54 ± 3%, p < 0.05). Cardiovascular events during admission were higher in the control group (five patients) than in the edaravone group (two patients). Three patients experienced ventricular tachycardia in the control group, as did two patients in the edaravone group. One patient experienced subacute thrombosis and one experienced cardiac death in the control group.
In the edaravone group, no patients suffered from any adverse effects from the use of edaravone, such as renal insufficiency or altered hepatic function.
Serial changes in plasma MCP-1 levels
The plasma MCP-1 levels were not different between the two groups before reperfusion; however, the plasma MCP-1 levels on day 3 after reperfusion were statistically lower in the edaravone group than in the control group (516 ± 66 pg/ml versus 873 ± 118 pg/ml, p < 0.05) (Fig. 1) . Moreover, plasma MCP-1 levels tended to be lower in the edaravone group than in the placebo group throughout the experimental course.
Long-term follow-up and heart failure requiring rehospitalization
At 12 months after reperfusion therapy, 44 of 45 patients were analyzed because one patient died in the acute phase. Heart failure requiring rehospitalization occurred in four patients in the control group, but did not occur in the edaravone group at 12 months after reperfusion therapy (p < 0.05). We subdivided the 44 AMI patients into two groups based on the presence (n = 4) or absence (n = 40) of heart failure requiring rehospitalization. The group with heart failure requiring rehospitalization was defined as R (+) group and the group without heart failure requiring rehospitalization as R (−) group. Plasma MCP-1 levels on day 3 in the R (+) group were statistically higher than in the R (−) group (1031 ± 91 pg/ml versus 629 ± 57 pg/ml, p = 0.029) ( Table 3 ). BNP levels in the R (+) group at 2 weeks after reperfusion therapy and rehospitalization were higher (437 ± 203 pg/ml at 2 weeks, 1126 ± 317 pg/ml at rehospitalization) than in the R (−) group (212 ± 43 pg/ml, at 2 weeks). LVEF at 2 weeks and at 12 months after reperfusion therapy were statistically lower in the R (+) group than in the R (−) group (45 ± 4% versus 58 ± 1% at 2 weeks, p < 0.01, 32 ± 1% versus 60 ± 1% at 12 months, p < 0.001). The use of diuretic drugs within 12 months after reperfusion therapy was needed 3 of 4 patients in the R (+) group, and 4 of 40 patients in the R (−) group (p = 0.010). The triggers of heart failure were associated with restenosis and arrhythmias.
Discussion
Early reperfusion has improved the clinical outcomes of patients with AMI. We have recently demonstrated that the administration of edaravone just before myocardial reperfusion attenuated both enzymatic infarct size and reperfusion arrhythmias in patients with AMI [19, 20] . However, the detailed mechanism underlying the cardioprotective effect with edaravone treatment remains unclear. Many experimental and clinical studies have demonstrated up-regulation of MCP-1 after MI, with recruitment of monocytes/macrophages to the ischemic myocardium [11] [12] [13] . Hayashidani et al. reported that an anti-MCP-1 gene therapy improved survival rate of mice as well as attenuated LV cavity dilatation and contractile dysfunction, interstitial fibrosis, recruitment of macrophages, and myocardial gene expression of tumor necrosis factor-␣, and transforming growth factor-␤ [21] . Thus, MCP-1 appears to be involved in myocardial ischemiareperfusion injury. In this study, we verified the clinical benefit of edaravone on infarct size and cardiovascular events and focused on plasma MCP-1 levels.
Our study indicated that the administration of edaravone just before reperfusion in AMI reduced plasma MCP-1 levels and cardiac damage (reduction of Max CK-MB and maintenance of cardiac function: EF). Plasma MCP-1 levels in the edaravone group were suppressed more than in the placebo group from day 1 to 14. A significant difference in MCP-1 levels between the two groups was observed by day 3. Murakami et al. reported a late increase in plasma MCP-1 levels in subacute phase in AMI patients [22] . A similar tendency was observed in our study. This finding is considered to be due to the accumulation of monocytes and macrophages within the infarcted myocardium in response to subsequent repair processes. Several studies have reported that MCP-1 also strongly promotes angiogenesis in the ischemic tissue [23] [24] [25] . Hayasaki et al. used immunohistochemical staining and showed that the number of macrophages in reperfused myocardium increased 6 h after reperfusion and peaked on day 3. Moreover, by blocking MCP-1 receptors, CCR-2 deficiency attenuated the migration and activation of macrophages during the initial reperfusion phase in AMI and reduced myocardial ischemiareperfusion injury [14] . Accordingly, we consider that edaravone inhibits the recruitment and attachment of monocytes/macrophages to reperfused myocardium during the first 3 days after AMI and reduces MCP-1 production in that tissue. That mechanism might contribute to favorable results in AMI patients.
In the clinical setting, we have previously investigated the correlation between reactive oxygen species (ROS) generation and coronary heart disease. Previous studies have demonstrated that oxidative stress markers, including plasma thioredoxin levels, urinary biopyrrins, 8-hydroxy-2deoxyguanosine, 8-epi prostaglandin (PG) F2alpha excretion, and 8-epi PGF2alpha levels from the great cardiac vein were elevated in patients with AMI [26] [27] [28] [29] [30] [31] [32] . These oxidative stress markers may predict subsequent cardiovascular events. Edaravone administration also reduced serum thioredoxin levels during the clinical course of AMI in the previous study. Serum thioredoxin levels after reperfusion therapy were significantly lower in the edaravone group than in the placebo group and especially in the subacute phase, serum thioredoxin levels remained at lower levels in the edaravone group than in the placebo group [20] . A similar ten-dency was also observed in the present study (data not shown).
Meanwhile, in patients who needed to be rehospitalized with heart failure, LVEF at discharge and at 12 months after reperfusion therapy was statistically lower than in patients who did not need to be rehospitalized in our study. In addition, plasma MCP-1 levels on day 3 were statistically higher in patients who needed to be rehospitalized with heart failure. Higher plasma MCP-1 levels on day 3 might induce lower LVEF and rehospitalization due to heart failure at 12 months after reperfusion therapy. Furthermore, LVEF at 12 months after reperfusion was statistically higher in the edaravone group than in the control group and heart failure requiring rehospitalization occurred during the chronic phase in the control group but not in the edaravone group. A recent study demonstrated elevated circulating levels of CC chemokines in patients with CHF [33] . The increase in CC chemokine levels was independent of the cause of heart failure, but particularly high MCP-1 levels were found in patients with coronary artery disease. The raised MCP-1 levels in serum from CHF patients enhanced spontaneous ROS generation in monocytes. This enhancement increased apoptosis of cardiomyocytes in patients with severe heart failure [34, 35] . Increased ROS generation in monocytes may further enhance the synthesis of MCP-1 in various cells through an autocrine mechanism [36] . From these findings, we suggest that edaravone inhibits MCP-1 production, thereby reducing cardiac damage in myocardial tissue. This mechanism might have contributed to the reduction in rehospitalization due to heart failure in the edaravone group.
The limitations of the present study include the relatively small sample size and open-label study because some patients were excluded from the dataset for loss of blood samples and apparently artifactual MCP-1 levels. Thus, further investigation is required to clarify the impact of reduction of plasma MCP-1 levels on cardiovascular events.
In conclusion, edaravone suppressed plasma MCP-1, improved LVEF, and reduced rehospitalization due to heart failure after reperfusion therapy. Suppression of plasma MCP-1 levels by edaravone might induce better prognosis for AMI patients.
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